人体中具有血管和淋巴管两套循环系统，两者存在相互交流和物质交换。淋巴系统位于动脉血管外膜和粥样硬化斑块表面，主要通过促进炎症细胞和介质回流发挥抑制动脉粥样硬化的作用。在NSFC项目支持下，我们发现血管内皮微颗粒携带的microRNA-19b可以促进动脉血管外膜炎症，进而加剧动脉粥样硬化进展；然而这一作用的途径和机制仍不清楚。本项目拟开展细胞和动物水平研究，重点探讨：（1）血管内皮微颗粒携带的microRNA-19b对淋巴系统的影响；（2）血管内皮微颗粒携带的microRNA-19b通过淋巴系统影响动脉粥样硬化进程；（3）血管内皮微颗粒携带的microRNA-19b调节淋巴系统与动脉粥样硬化进程的机制。旨在阐明血管内皮微颗粒携带的microRNA-19b通过调节淋巴系统参与动脉粥样硬化的作用途径和分子机制，为动脉粥样硬化防治提供新的作用靶点与机制解释。

Two circulatory systems exit in the human body: blood vessels and lymphatic vessels, which communicate with information and exchange with materials each other. The lymphatic system is located in the adventitia of arteries and atherosclerotic plaque, and plays a key role in inhibiting atherosclerosis mainly by the draining of inflammatory cells and cytokines. With the support of NSFC project, we found that endothelial microparticles (EMPs)–derived microRNA-19b can promote the inflammation of the arterial adventitia, thus aggravating the progression of atherosclerosis. However, the pathways and mechanisms of this effect have not been elucidated. This present project intends to investigate the following contents in vivo and vitro: (1) EMPs-derived microRNA-19b regulates biological effects of lymphatic system; (2) EMPs-derived microRNA-19b regulates the process of atherosclerosis through the lymphatic system; (3) The mechanism underlies EMPs-derived microRNA-19b in regulating the lymphatic system and process of atherosclerosis. The purpose of this study is to elucidate the pathways and molecular mechanisms of EMPs-derived microRNA-19b in aggravating atherosclerosis through the regulation of the lymphatic system, and to offer a novel target and mechanism explanation for atherosclerosis prevention and treatment.